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Erol Fikrig,* Stephen W. Barthold,² Wei Sun,³ Other evidence for variation of B. burgdorferi gene ex-
Wen Feng,³ Sam R. Telford III,§ pression within the vertebrate host also exists: eppa,
and Richard A. Flavell³ pG, bbk2.10, and several ospE/F homologs appear to
*Section of Rheumatology be selectively expressed in vivo (Champion et al., 1994;
Department of Internal Medicine Wallich et al., 1995; Akins et al., 1996; Marconi et al.,
²Section of Comparative Medicine 1996; Montgomery et al., 1996; Stevenson et al., 1996).
³Section of Immunobiology and Howard Hughes The humoral response to B. burgdorferi antigens ex-
Medical Institute pressed within the vertebrate host may also aid in the
Yale University School of Medicine serologic diagnosis of Lyme disease. Enzyme-linked
New Haven, Connecticut 06520 immunosorbent assay (ELISA) and immunoblots based
§Department of Tropical Public Health on whole-cell lysates of B. burgdorferi may not detect
Harvard University School of Public Health antibodies directed toward proteins preferentially ex-
Boston, Massachusetts 02115 pressed in vivo because these antigens may not be
present on cultured spirochetes (Magnarelli, 1989; Dres-
sler et al., 1993; Johnson et al., 1996). The inability to
detect antibodies directed toward in vivo±expressedSummary
antigens may be one reason why current serologic tests
for Lyme disease remain difficult to interpret. In addi-p35 and p37 are Borrelia burgdorferi genes encoding
tion, the humoral response of B. burgdorferi±infected35and 37 kDa proteins. Thegene products were identi-
mice to in vivo±expressed proteins has powerful bio-fied by differential screening of a B. burgdorferi ex-
logic effects, which may lead to the discovery of newpression library with sera fromB. burgdorferi infected±
vaccine strategies. Very small amounts of sera fromand B. burgdorferi±hyperimmunized mice. Northern
actively infected mice (immune sera), when passivelyblot and RT-PCR analyses confirmed that these genes
transferred to naive mice, confer protection againstwere selectively expressed in vivo. ELISA, using P35
high-dose B. burgdorferi challenge. Remarkably, theand P37, showed that infected mice (5 of 5, 100%)
protective activity of immune sera peaks at 30 days ofand patients (31 of 43, 72%) with Lyme borreliosis
infection, then declines throughout the course of persis-developed P35 or P37 antibodies. Mice developed
tent infection, unlike the progressive rise in antibodypeak IgG titers to P35 and P37 within 30 days, followed
directed against antigens derived from cultured B. burg-by decline. Mice given both P35 and P37 antisera were
dorferi (Barthold and Bockenstedt, 1993). Immune seraprotected from challenge with 102 B. burgdorferi, and
have also been shown to induce arthritis resolution inP35 and P37 antisera also afforded protection when
actively infected severe combined immunodeficientadministered 24 hr after spirochete challenge. The use
of in vivo±expressed antigens such as P35 and P37 (SCID) mice (Barthold et al., 1996). Thus, identification
represents a new approach for Lyme disease serodi- of in vivo±expressed antigens of B. burgdorferi offers
agnosis and for understanding the role of B. burgdorf- the opportunity for the development of more accurate
eri±specific immune responses in host immunity. serodiagnostic antigens, preventive vaccines, and pos-
sibly therapeutic vaccines.
We recently developed a differential screening strat-
Introduction egy to identify B. burgdorferi genes that may be selec-
tively induced in vivo. In this approach, a B. burgdorferi
Borrelia burgdorferi, the spirochetal agent of Lyme dis-
genomic DNA expression library was probed with two
ease, undergoes dramatic alterations of its outer surface
sets of sera: immune sera from mice infected with B.proteins during different stages of its life cycle in Ixodes
burgdorferi and hyperimmune sera from mice immu-scapularis (also known as Ixodes dammini) ticks and in
nized with killed spirochetes (Suk et al., 1995). Plaquesthe mammalian host (Barthold et al., 1995; Fingerle et
reactive with immune, but not hyperimmune, sera reflectal., 1995; Schwan et al., 1995; de Silva et al., 1996). For
genes that are differentially expressed in vivo. One suchexample, outer surface protein (Osp) C is not expressed
identified gene, p21, was shown to be expressed in vivoby spirochetes within unfed ticks; however, following
using Northern blot and reverse transcriptase polymer-introduction of a blood meal into the tick midgut, B.
ase chain reaction (RT-PCR), and 14 additional phageburgdorferi synthesize OspC (Schwan et al., 1995). Con-
plaques that correspond to five groups of genes andversely, OspA is a prominent antigen on spirochetes
that may encode other in vivo±expressed proteins werewithin the midguts of flat ticks and is down-regulated
isolated (Suk et al., 1995). In this report we describe theor lost while spirochetes migrate from the midgut to the
identification of two immunogenic proteins, P35 andsalivary gland in the feeding tick (de Silva et al., 1996).
P37, that are expressed early during B. burgdorferi infec-Once spirochetes have entered the mammalian host,
tion of mice and that are recognized by serum fromthey areno longer vulnerable toOspA-induced immunity
human Lyme disease patients. P35 and P37 are promis-(Barthold et al., 1995; de Silva et al., 1996). OspC and
ing targets for diagnostic tests or vaccines for the pre-OspA serve as a paradigm for the significant changes
that occur in different adaptive forms of the spirochete. vention of Lyme disease.
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Results p37 following infection with 102 B. burgdorferi, further
suggesting that these antigens are expressed in vivo
(Figures 4A and 4B). Immunoglobulin (Ig) G to both P35Identification of p35 and p37
Previous differential screening of a lambda ZAP II B. and P37 could be detected as early as 14 days after
infection and peaked at 30 days. By 60±90 days follow-burgdorferi expression library with immune serum from
mice infected with B. burgdorferi for 90 days and also ing infection, these antibody responses had diminished
and practically disappeared by 180 days. In contrast,with hyperimmune serum from mice immunized with
heat-killed spirochetes revealed 14 phage clones that IgG to B. burgdorferi whole-cell lysates continued to
increase with persistent infection (Figure 4C). Since spi-represented five B. burgdorferi genes (or members of
gene families) that expressed antigens selectively reac- rochetes are normally transmitted by tick bite, we mea-
sured the antibody response to P35 and P37 in micetive with immune sera (Suk et al., 1995). Two of these
five groups of clones now also showed strong reactivity infected with B. burgdorferi following tick bite. At 14
days following tick-borne infection, antibodies to P35with antibodies in the immune sera of 30-day infected
mice. The genes encoding these two immunogenic anti- and P37 were detectable by immunoblot (Figure 4D).
gens were sequenced and designated p35 and p37.
p35 and p37 had open reading frames of 927 and 996
Patients with Lyme Disease Developnucleotides, respectively (Figures 1A and 1B). 235 and
P35 and P37 Antibodies210 regions as well as ribosome binding sites were
We assessed the human IgM and IgG responses to P35identified upstream of the respective open reading
and P37 using a reference panel of 43 sera from patientsframes. The deduced amino acid sequence of P37 re-
with well-documented Lyme disease that were carefullyvealed a phenylalanine-X-Y-cysteine motif and a hy-
selected by the Centers for Disease Control (Fort Collins,drophobic leader sequence, consistent with a lipopro-
Colorado). Twenty-seven of the individuals were culture-tein. Pulsed-field gel electrophoresis demonstrated that
positive for B. burgdorferi, including 25 patients withboth these genes are encoded on different plasmids:
erythema migrans (skin) and 2 individuals with meningi-p35 and p37 are on plasmids with the mobility of a 42
tis (cerebrospinal fluid). Overall, 31 of the 43 (72%) pa-and 16 kb linear DNA, respectively (Figure 1C).
tients had IgG or IgM to P35 and/or P37 by ELISA,
including 24 of 33 patients with early-stage disease and
p35 and p37 Are Expressed In Vivo 7 of 10 patients with late-stage disease (Table 1). Thirty-
Because the differential immunologic screening sug- four of these 43 patients (79%) tested positive for Lyme
gested that these antigens are selectively synthesized disease in immunoblots using B. burgdorferi whole-cell
in vivo, we performed further molecular studies. RNA lysates as the substrate: the 9 patients who tested nega-
from cultured B. burgdorferi was probed with p35 and tive in both assays uniformly had early disease that was
p37 in Northern blot analyses. p35 and p37 RNA were effectively treated with antibiotics, and were culture-
not detected, while ospA RNA (control) was identified positive from biopsy specimens of the erythema migrans
(Figure 2A). In addition, ospA, but not p35 or p37, could lesion. IgM to P35 or P37 and IgG to P35 and P37 were
be identified in RNase protection assay using RNA from evident in 11, 8, 23, and 25 of these 43 individuals,
cultured spirochetes (Figure 2C) and RT-PCR using RNA respectively. As shown in Figure 5, pooled sera (1:100
from cultured B. burgdorferi showed a band consistent dilution) from a group of 5 individuals with well-docu-
with ospA, but not p35 or p37 (Figure 2B). To ensure mented Lyme disease had strong IgG and IgM re-
that the B. burgdorferi used in the assays contained p35 sponses to glutathione transferase (GT)±P35 (IgG: opti-
or p37 DNA, Southern dot blot analyses were performed: cal density [OD] 1.43 6 0.24; IgM: OD 0.72 6 0.15) and
as expected, DNA for ospA, p35, and p37 could be GT-P37 (IgG: OD 1.13 6 0.31; IgM: OD 0.39 6 0.08) and
detected (Figure 2D). little reactivity to GT (IgG: OD 0.12 1 0.04; IgM: 0.17 6
We then used a variety of strategies to show that p35 0.04). The mean OD values for the 43 patient sera were
and p37 were selectively expressed in vivo. Total RNA as follows: GT-P35 (IgG 0.46 6 0.12 and IgM 0.38 6
was harvested and subject to RT-PCR. In the first few 0.14), GT-P37 (IgG 0.48 6 0.10 and IgM 0.36 6 0.09),
days of infection, when spirochetes are localized to the and GT-P37 (IgG 0.11 6 0.04 and IgM 0.25 6 0.14).
site of inoculation, p35 and p37 mRNA could not be Representative ELISA results using sera from selected
detected in the skin (at the place of spirochete injection), patients are presented in Figure 5. Sera from 4 healthy
whereas flagellin mRNA (control) was readily amplified individuals, 5 patients with a history of syphilis and a
(Figures 3A and 3B). As expected, p35, p37, or flagellin reactive VDRL, and 5 patients with systemic lupus ery-
mRNA could not be identified at distant skin sites or the thematosis or rheumatoid arthritis did not have detect-
spleen (Figure 3E) at these early time points because able antibodies to P35 and P37.
spirochetes had not yet disseminated from the inocula-
tion site and could not be cultured from spleen or skin.
At 7 and 14 days, when spirochetes had migrated from P35 and P37 Elicit Protective Immunity against
Experimental B. burgdorferi Infectionthe site of inoculation, p35 and p37 mRNA became de-
tectable at the initial site of infection (Figures 3C and Because P35 and P37 are synthesized in the early
stages of mammalian infection, we sought to determine3D). In addition, p35 and p37 mRNA could be amplified
by RT-PCR from distant skin and spleen that had been whether the immune response to P35 and/or P37 could
induce protective immunity in mice (Table 2). Vaccina-infected for 7 or 14 days (Figures 3F, 3G, and 3H).
Mice developed a strong humoral response top35 and tion with both P35 and P37 was protective against a
B. burgdorferi P35 and P37 Immunity In Vivo
533
Figure 1. Sequences of p35 and p37
The nucleotide and deduced amino acid sequences are depicted
for p35 (A) and p37 (B). The putative ribosome binding site (RBS)
and 210 and 235 promoter regions are underlined. Asterisks indi-
cate the stop codon. (C) B. burgdorferi DNA separated by pulsed-
field gel electrophoresis and probed with p37 (lane 1) and p35 (lane
2). These sequences are available from GenBank, Bankit identifica-
tion number 85537.
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Figure 3. p35 and p37 Are Expressed in Murine Skin 7 Days after
Experimental Infection
Figure 2. Selective Expression of p35 and p37 In Vivo Ethidium bromide±stained gel of RT-PCR products amplified from
B. burgdorferi RNA recovered from skin or spleen 1, 2, 3, 7, or(A) Northern blot of B. burgdorferi RNA probed with p35 (lane 1),
p37 (lane 2), or ospA (lane 3). (B) RT-PCR of B. burgdorferi RNA 14 days after inoculation with 104 spirochetes. Skin samples were
obtained from the site of inoculation at 1 (A), 2 (B), 7 (C), and 14 (D)using p35-specific (lane 1), p37-specific (lane 2), or ospA-specific
(lane 3) primers (with [1] and without [2] RT). (C) RNase protection days. Skin samples were obtained from distant locations at 3 (E)
and 14 (F) days, and spleen at 7 (G) and 14 (H) days. p35, p37,assays using B. burgdorferi RNA and p35 (lane 2), p37 (lane 3), or
ospA (lane 4) DNA fragments. Lane 1, molecular mass markers. (D) and flagellin (fla) primers were used for amplification (with [1] and
without [2] RT). M, molecular mass markers.Southern blot of B. burgdorferi DNA probed with p35 (lane 1), p37
(lane 2), or ospA (lane 3).
plays in the evolution of Lyme disease. For example,
while OspA is an abundant antigen on cultured spiro-
challenge dose of 104 spirochetes compared to GT-vac-
chetes and on B. burgdorferi within flat ticks, OspA is
cinated mice (x2, p # 0.01). Active immunization with
down-regulated when ticks engorge (de Silva et al.,
P35 alone provided partial protection against 104 spiro- 1996). The extent to which ospA is expressed during
chetes. Passive transfer of both P35 and P37 hyperim-
mammalian infection needs to be explored further, but
mune sera provided full protection against 102 (x2, p # several studies suggest that OspA is not abundant dur-
0.01), but not 104, spirochetes compared to GT-immu- ing infection. When OspA-immune mice are challenged
nized mice. Moreover, P35 and P37 hyperimmune sera with host-adapted spirochetes, they develop dissemi-
were also able to provide immunity when administered nated infection and disease, suggesting that spiro-
to mice that had been infected with 102 spirochetes for chetes are not vulnerable to OspA immunity once
24 hr compared to GT-immunized mice (x2, p # 0.01). adapted to the host (Barthold et al., 1995). Moreover,
In all cases when mice were infected, the severity of OspA antibodies are ephemeral during early human
arthritis was similar, regardless of treatment group, sug- Lyme disease, and ospA mRNA is difficult to detect in
gesting that once infection occurred, P35 or P37 immu- the initial period of murine infection (Schutzer et al.,
nity did not influence evolution of ensuing disease. 1994; Kalish et al., 1995; Montgomery et al., 1996). Alter-
natively, OspA antibodies in the later stages of murine
Discussion and human infection (particularly in patients with antibi-
otic-resistant chronic arthritis), as well as the identifica-
These studies characterize p35 and p37, B. burgdorferi tion of OspA-specific T cells in individuals with Lyme
genes that appear to be expressed in the early stages arthritis, imply that at some point during infection ospA
of mammalian infection. Because B. burgdorferi can al- is expressed (Yssel et al., 1991; Fikrig et al., 1992; Kalish
ter its antigenic structure, it is important to understand et al., 1993). The degree to which and the reasons why
the extent to which variation occurs and the role that the B. burgdorferi surface protein synthesis changes during
the spirochetal life cycle are not known.immune response to selectively synthesized proteins
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Figure 4. Antibodies to P35 and P37 Elicited during the Course of Murine Lyme Borreliosis
Sera from mice infected with 102 B. burgdorferi for 7±180 days were used in ELISA with recombinant P37 and P35 GT fusion proteins as
substrates. IgM (A) or IgG (B) antibodies. (C) IgM and IgG to B. burgdorferi whole-cell lysates in infected mice. (D) Immunoblot of GT-P37,
GT-P35, and GT probed with sera (1:100 dilution) from mice infected with B. burgdorferi by tick bite for 7 (lane 1), 14 (lane 2), 30 (lane 3), 90
(lane 4), and 180 (lane 5) days.
P35 and P37 were first identified by differentially The kinetics of both P35 and P37 antibody responses
during persistent B. burgdorferi infection of mice arescreening a B. burgdorferi expression library with im-
mune sera from B. burgdorferi±infected mice and ani- striking, with peak antibody responses within 30 days of
infection, followed by decline. This suggests that thesemals hyperimmunized with heat-killed spirochetes. This
technique previously identified p21, an ospE homolog antigens are priming an immune response only during
the early stages of infection. It is notable that identicalthat is induced in vivo (Suk et al., 1995). To identify p21,
the library was probed with immune sera from mice antibody kinetics occur when the passive protective ac-
tivity of immune serum is titrated in persistently infectedinfected with B. burgdorferi for 180 days. In contrast,
when p35 and p37 were found, the library was screened mice. In contrast, IgG to B. burgdorferi whole-cell ly-
sates increases from 30 to 90 days, and antibodies towith sera obtained from mice infected for 30 and 90
days, in an effort to facilitate the identification of genes an antigen that is likely to be constitutively expressed
(flagellin) continue to be present in high titer. The parallelthat are induced in the early stages of infection. The
detection of P35 and P37 with immune sera from mice kinetics of P35 and P37 antibody with protective anti-
body kinetics suggests that P35 and P37 are amongduring early but not later stages of infection may explain
why p35 and p37 were not uncovered in the initial the antigens likely to be responsible for the protective
activity in sera of actively infected mice.screening strategy (using 180-day immune sera) that
revealed p21. The selective induction of p35 and p37 in Since p35 and p37 expression occurs early in infec-
tion, we sought to determine the role of P35 and P37the mammalian host and the lack of in vitro expression
were confirmed bythe detection of p35 and p37 mRNA in antibodies in immunity. Immune sera from B. burgdorf-
eri±infected mice have the capacity to both protect miceB. burgdorferi±infected murine tissue but not in cultured
spirochetes, and the presence of P35 and P37 antibod- from infection, eliminate infection up to 4 days after
inoculation, and induce arthritis resolution in activelyies in the serum of infected mice and patients with Lyme
disease. infected mice, whereas hyperimmune sera to heat-killed
Immunity
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Table 1. P35 and P37 ELISA Analysis of Sera from Patients with Lyme Disease
ELISA
P35 P37
Symptom B. burgdorferi Immunoblot
(no. of patients) IgM IgG IgM IgG (no. positive/total)
Erythema migrans
(4) 1 1 1 1 4/4
(4) 2 1 2 1 3/4
(5) 2 1 2 1 5/5
(6) 2 2 2 1 3/6
(1) 1 2 1 2 1/1
(3) 1 1 2 2 3/3
(1) 2 1 2 2 1/1
(9) 2 2 2 2 4/9
Arthritis
(1) 1 1 1 2 1/1
(2) 1 2 1 2/2
(1) 2 2 2 1 1/1
(3) 2 2 2 2 3/3
Neurologic disease
Meningitis (2) 1 1 1 1 2/2
Facial palsy (1) 2 1 2 1 1/1
B. burgdorferi-whole-cell lysate based immunoblots (IgM and IgG) were assessed by the Centers for Disease Control according to the banding
criteria established by Dressler et al. (1993).
spirochetes is only protective but does not influence the early stages of murine and human Lyme borreliosis
also suggests that P35 and P37 antibodiesmay be usefulinfection or disease after inoculation (Barthold et al.,
1996). This unique capacity of immune serum to clear markers of infection. Current serologic assays, including
ELISA and immunoblot, that detect exposure to B. burg-B. burgdorferi during early infection, suggests the re-
sponse to in vivo induced antigens is responsible for dorferi use whole-cell lysates of cultured spirochete as
the substrate and therefore cannot detect antibody re-this effect. Indeed, antibodies to OspA (with profound
protective capabilities in vaccine studies) are abundant sponses to proteins expressed in vivo (Stanek et al.,
1987; Magnarelli, 1989; Dressler et al., 1993). This isin the sera of mice hyperimmunized with heat-killed spi-
rochetes but cannot eliminate the pathogen once infec- likely to result in an incomplete assessment of the im-
mune response to B. burgdorferi. Studies analyzing thetion is established (Fikrig et al., 1993). Sera from B.
burgdorferi±infected mice recognized flagellin, P39, and temporal development of the human and murine re-
sponse to B. burgdorferi using whole-cell lysate±basedOspC on immunoblot, suggesting that antibodies to
these proteins may elicit the protective, postinfectious, systems have indicated that, in general, antibodies to
flagellin, P39, and OspC appear in the early stages ofor disease-modulating effect of immune serum. How-
ever, when antisera against these specific proteins were disease and that antibodies to numerous spirochetal
antigens develop as the infection continues (Dressler etadministered to B. burgdorferi±infected mice, no effects
were noted (Barthold et al., 1996). Our current studies al., 1993; Barthold et al., 1995; Barthold et al., 1996;
Magnarelli et al., 1996). While antibodies to these pro-show that P35 and P37 antisera have the capacity to
protect mice from infection, when administered both teins certainly are elicited during infection (suggesting
that many antigens are expressed both in vitro and inprior to and 24 hr after B. burgdorferi challenge. There-
fore, P35 and P37 antibodies provides a basis for under- vivo), the response to in vivo induced gene products is
not discernible using standard assays. Our data suggeststanding the protective capacity of sera from B. burg-
dorferi±infected mice. that the evolution of the humoral response is more com-
plex that previously considered. Indeed, it is likely thatThe data also indicate that p35 and p37 are expressed
several days after the spirochetes are introduced into several genes are induced or inhibited at various stages
of infection and that current detection methods are un-the skin. p35 and p37 mRNA could not be detected in
biopsy specimens from the site of experimental inocula- able to identify antibodies to these antigens because
they lack the ªin vivoº antigen. This paradigm may ex-tion for up to 48 hr but could be identified in skin and
tissue specimens at 7 and 14 days. During experimental tend beyond Lyme disease and apply to other microbes
that result in persistent infection.murine Lyme borreliosis, spirochetes disseminate from
the initial skin lesion at 3±5 days and then spread hema-
Experimental Procedurestogenously to visceral organs and other cutaneous sites
(Barthold et al., 1991). p35 and p37 expression tempo-
B. burgdorferirally coincides with the spread of B. burgdorferi, and this
B. burgdorferi isolate N40 (cloned N40) with proven infectivity and
suggests that p35 and p37 may play a role in spirochete pathogenicity in mice was used throughout the study (Barthold et
migration or tissue invasion. al., 1995). Spirochetes were grown in Barbour-Stoenner-Kelly (BSK)
II medium at 338C for use in all the experiments (Barbour, 1984).The prominent humoral response to P35 and P37 in
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transferase fusion protein) or GT-P37 (recombinant P37 prepared
as a GT fusion protein) in CFA and boosting the animal twice over
a period of 1 month; in each case the P35 or P37 antibodies were
present at a titer of 1: 25,000 by immunoblot). GT antisera (control)
were prepared in an identical fashion.
Library Screening
A lambda ZAP II genomic expression library of B. burgdorferi N40
was used (Lam et al., 1994). The phage plaques were probed with
immune sera from 30 day±infected mice and hyperimmune sera
from B. burgdorferi±hyperimmunized mice. Sera (1: 100 dilution in
phosphate-buffered saline [PBS]) were used as the primary anti-
body. Secondary antibodies were goat anti-mouse immunoglobulin
conjugated to alkaline phosphatase and were detected following
incubation with nitroblue tetrazolium (NBT) and 5-bromo-4-chloro-
3-indolyl-phosphate (BCIP). Plaques that reacted uniquely with im-
mune sera but not hyperimmune sera were subjected to secondary
and tertiary screening. pBluescript plasmids that contained genes
encoding reactive antigens were excised using the R408 helper
phage (Lam et al., 1994). The nucleotide sequences of the genes
encoded on the plasmid inserts were then determined using the
Circumvent Thermal Cycle Dideoxy DNA sequencing kit (New En-
gland Biolabs) and designated p35 and p37 respectively, based on
the estimated size of the gene products.
Pulsed-Field Gel Electrophoresis
Pulsed-field gel electrophoresis was performed with B. burgdorferi
DNA (Lam et al., 1994). DNA plugs containing approximately 105 B.
burgdorferi N40 were loaded onto a 0.8% agarose gel and run in
Tris-borate-EDTA buffer (0.025 M Tris, 0.5 mM EDTA, 0.025 M boric
acid), using the Chef-DRIIsystem (Bio-Rad Laboratories, Richmond,
CA). The gel was run at 148C for 18 hr at 198 V, with ramped pulse
times from 1 to 30 s. Southern blotting was carried out with p35
and p37 probes labeled with (a-32P)dCTP, using the Prime-It random
primer kit (Stratagene, La Jolla, CA).
Northern Blot Analysis
Total RNA was isolated from cultured B. burgdorferi by acid guanidi-
nium thiocyanate phenol-chloroform extraction. Ten micrograms of
the recovered RNA was electrophoresed in a 1% formaldehyde-
agarose gel and blotted onto a Hybond-N-membrane. The blotted
membrane was prehybridized in 50% formamide for 1 hr at 428C,
Figure 5. ELISA (IgM and IgG) Using Recombinant GT-P35 or GT- and then hybridized, using the same conditions, with probes for p35,
P37 as the Substrate and Sera from Representative Patients with p37, or ospA overnight. Random-primed 32P-labeled DNA inserts
Lyme Disease encoding p35 (920 bp), p37 (960 bp) and ospA (800 bp) were used
as probes. The membranes were washed in 0.1 3 SSC and 0.1%The serologic responses of 8 individuals, 5 with erythema migrans
SDS at 558C prior to exposure and development of film.(the second and fourth patients were culture-positive), 3 with arthri-
tis, and 1 with meningitis, are shown. Positive control sera (pos.
control) are pooled from 5 patients with well-documented Lyme RNase Protection Assays
The extracted RNA from cultured B. burgdorferi was hybridized withdisease, from our clinic at Yale, with IgG or IgM antibodies to B.
burgdorferi whole-cell lysates. Negative control sera are pooled a 32P-labeled cRNA probe made from subcloned DNA containing
selected B. burgdorferi genes, p35 (AccI, 190 bp), p37 (XmnI, 390from 3 healthy individuals.
bp) and ospA (PstI, 180 bp). The DNAs that spanned regions of
p37 (nucleotides 606±996), p35 (nucleotides 737±927), and ospA
(nucleotides 642±822) were subcloned into pBluescript. The anti-Mice
sense and sense 32P-UTP±labeled cRNA probes were transcribedThree-week-old female C3H/HeNCr (C3H) mice were obtained from
using T7 and T3 polymerase. Template DNA was removed usingthe Frederick Cancer Research Center (Frederick, MD). Mice were
RNase-free DNase. The RPA II ribonuclease protection assay kithoused in filter-frame cages and euthanized with carbon dioxide.
(Ambion, Austin, TX) was utilized for hybridization, RNase digestion
and electrophoretic separation. The gel was exposed to film for 24Antibodies
hr. Sense probes produced no hybridization.Sera were obtained from mice infected (immune sera) orhyperimmu-
nized (hyperimmune sera) with B. burgdorferi. For infection, mice
were given with an intradermal inoculation of 102 B. burgdorferi N40. PCR
Conditions for PCR amplification of B. burgdorferi DNA were 30Sera were obtained from the animals at 7, 14, 28, 42, 60, 90, 180,
and 270 days. All the mice had verified infection based on culture cycles with a denaturing, annealing and extension temperature of
948C for 1 min, 558C for 1 min, and 728C for 2 min. 59 and 39 primersof spleen, urinary bladder, and/or skin. For hyperimmunization,
groups of 5 mice were injected with 107 heat-killed spirochetes in for PCR were 59-GCGGTGAAAGTGGT GAATTGG-39 and 59-CTTTA
GCAAAGTTGTCAAGGCGTG-39 for p35; 5-GACAA CAACAGAAGTGcomplete Freund's adjuvant (CFA) and given booster injections at
2 and 4 weeks with the same number of B. burgdorferi in incomplete GTCGCAC-39 and 59-TAGCATCGGAATGAGCTGTGCC-39 for p37;
59-TCTGACGATCTAGGTCAAACCACA-39 and 59-CCCTCTAATTTGFreund's adjuvant (IFA). Mice hyperimmunized with heat-killed B.
burgdorferi were culture-negative at the time of sacrifice. P35 or GTGCCATTTG-39 for ospA; and 59-CAATCAGGTAACGGC-39 and
59-TCTATTTTGGAAAGC-39 for flagellin. For RT-PCR, total RNA wasP37 antisera were prepared by hyperimmunizing a rabbit with 50
mg of either GT-P35 (recombinant P35 prepared as a glutathione isolated from the spleens, or the skin (5 mm section) of mice infected
Immunity
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Table 2. Lyme Borreliosis in C3H Mice Immunized with P35 or P37
Challenge
Immunogen (no. of spirochetes) Arthritis Carditis Culture-positive Infection
Active
P35 104 5/9 5/9 5/9 5/9
P37 104 6/9 8/9 8/9 8/9
P35 and P37 104 2/10 1/10 2/10 2/10
GT (control) 104 7/12 9/12 11/12 12/12
Passive
P35 antiserum 104 4/5 3/5 4/5 4/5
P37 antiserum 104 3/5 3/5 3/5 3/5
P35 and P37 antisera 104 3/5 3/5 3/5 4/5
102 0/7 0/7 0/7 0/7
102, 24 hr post 1/10 1/10 1/00 1/10
GT (control) antiserum 104 3/5 3/5 3/5 4/5
102 7/9 6/9 5/9 8/9
104, 24 hr post 8/10 6/10 10/10 10/10
In the active immunization studies, P35- and/or P37- or GT (control)±vaccinated mice were challenged with inocula of 102 or 104 B. burgdorferi
14 days after the final boost and then killed at 14 days. In the passive immunization studies, mice were administered rabbit P35- and/or P37
hyperimmune sera or anti-GT hyperimmune serum (control). The antisera were given to the animals 1 day prior to or 24 hr after (24 hr post)
challenge with B burgdorferi. Blood, urinary bladder, spleen, and skin punches were cultured in BSK II medium for 2 weeks and examined
by dark-field microscopy for spirochetes. The tibiotarsi and heart were examined microscopically for inflammation. Mice from which B.
burgdorferi were isolated from at least one tissue specimen and/or had evidence of disease were considered to be infected.
with B. burgdorferi for 14 days, or from spirochetes cultured in ELISA
For ELISA, duplicate sets of 96-well microtiter plates were coatedBSK II medium, by acid guanidinium thiocyanate phenol-chloroform
with antigen (200 mg [1 mg/ml, 200 ml/well] of recombinant GT, GT-extraction (Suk et al., 1995). Pooled RNA was then treated with
P35, or GT-P37) and incubated overnight at 48C. Plates were thenDNase and RNA inhibitor (Promega, Madison, WI) for 3 hr at 378C.
washed three times with 0.05% PBS Tween (PBST). Triplicate sam-Two micrograms of pooled RNA was reverse transcribed by rTth
ples of patient or murine immune sera (200 ml/well, diluted 1:100)DNA polymerase (Perkin Elmer, Branchburg, NJ). ªDownstreamº
were then applied to the coated plates and incubated for 1 hr atprimers for either p35, p37, or ospA were then added. The reactions
room temperature. Plates were then washed three times with PBST.were carried out at 708C for 15 min. ªUpstreamº primers and MgCl2
Goat anti-human or goat anti-mouse IgM and IgG, each dilutedsolution were then added as suggested by the manufacturer. PCR
1:2000 and linked to alkaline phosphatase, were then added to eachwas carried out for 30 cycles of 948C for 1 min, 538C for 1 min, and
well. Plates were incubated at room temperature for 1 hr and washed728C for 2 min.
three times with PBST, and then 200 ml of freshly prepared
p-nitrophenol phosphate, (1 mg/ml in glycine buffer, pH 10.5) was
added to each well and monitored at 405 nm. The reaction wasProtein Purification
stopped with 3 M NaOH.Recombinant P35 and P37 were expressed as fusion proteins with
GT. The p35 and p37 genes were cloned into pMX, a modified pGEX-
2T vector (Sears et al., 1991). To facilitate subcloning, the p35 and Immunoblots
p37 genes were amplified using 59 primers with an additional XhoI Recombinant GT-P35 or GT-P37 were resolved in 12% minigels
(for p35) and BamHI (for p37) restriction enzyme digestion site and by SDS PAGE and transferred to nitrocellulose membranes. One
a 39 primer with a supplementary HindIII (for p35) or XhoI (for p37) microgram of recombinant antigen was loaded on each lane. The
site. Plasmid DNA obtained from initial phage colonies was used nitrocellulose strips containing recombinant protein were then
as the template for p35 and p37. Amplified gene products were probed with antiserum (diluted 1:100). The secondary antibody was
digested with either XhoI and BamHI or HindIII and XhoI and cloned alkaline phosphatase conjugated goat anti-mouse or anti-human
into the corresponding sites in the pMX plasmid. The ligation mixture immunoglobulin. Color development was performed using NBT and
was then used to transform Escherichia coli DH5a, and colonies BCIP.
containing the recombinant plasmid were isolated on Luria broth
supplemented with ampicillin. Immunization Studies
Recombinant fusion protein production was induced by growing Groups of 5 mice were hyperimmunized subcutaneously with 10 mg
the bacteria to logarithmic phase and adding 1 mM isopropyl-1- of recombinant GT-P35 and/or GT-P37 in CFA and boosted at 14
thio-b-galactoside (IPTG) for 3 hr. The E. coli were then placed in and 28 days with the same amount of antigen in IFA, according to
PBS with 1% Triton and subjected to sonication. The cell superna- published protocols (Fikrig et al., 1990). Control mice were hyperim-
tant and pellet were separated by centrifugation at 1000 3 g for 8 munized with recombinant GT in an identical fashion. Fourteen days
min. Recombinant fusion proteins present in the supernatant were following the last boost, sera from the hyperimmunized animals was
then purified by passage over a glutathione column (Fikrig et al., used to probe recombinant P35 or P37 (prepared without the GT
1990). The fusion proteins, GT-P35 or GT-P37, were eluted from the fusion partner) to determine the presence and titer of specific anti-
column using a solution containing excess glutathione and quanti- body. Hyperimmunized mice were challenged 14 days after the last
fied. Recombinant GT (control antigen) was prepared in an identical boost with intradermal inoculations of 102 or 104 spirochetes. In
fashion. Purified P35 and P37, without the GT fusion partner, were passive immunization studies, mice were administered 0.2 ml of GT-
also obtained, for the pMX vector contains a thrombin cleavage P35 and/or GT-P37 hyperimmune sera. Control mice were given GT
site immediately following the GT protein. After the supernatant hyperimmune sera. Passively immunized mice were challenged with
containing the recombinant P35 or P37 fusion protein was passed 102 or 104 B. burgdorferi either 24 hr prior to or 24 hr after passive
onto the glutathione column, a solution containing thrombin was immunization. In all the studies, mice were killed 14 days after chal-
added to the column to cleave the recombinant proteins from the lenge.
At necropsy, blood, spleen, urinary bladder and skin punchesglutathione transferase.
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from the animals were collected aseptically, cultured in BSK II me- Borrelia burgdorferi in Ixodes ricinus. J. Clin. Microbiol. 33, 1867±
1869.dium, and examined by dark-field microscopy for spirochetes. The
joints and the hearts were formalin fixed, paraffin embedded, sec- Johnson, B.J., Robbins, K.E., Bailey, R.E., Cao, B.L., Sviat, S.L.,
tioned, and examined microscopically for inflammation. Tibiotarsal Craven, R.B., Mayer, L.W., and Dennis, D.T. (1996). Serodiagnosis
arthritis was graded by blinded analysis on a scale from 1 (mild) to of Lyme disease: accuracy of a two-step approach using a flagella-
3 (severe) as described (Fikrig et al., 1995). based ELISA and immunoblotting. J. Infect. Dis. 174, 346±353.
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